XML 71 R60.htm IDEA: XBRL DOCUMENT
v3.7.0.1

Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator (Details) - USD ($) $ in Thousands | Jun. 30, 2017 | Dec. 31, 2016
--- | --- | ---
Deferred Revenue Arrangement [Line Items] |  |  |
Deferred revenue |  | $ 285,318 | $ 310,142
Upfront and Milestone Payments |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |
Deferred revenue |  | 278,262 | 297,867
Upfront and Milestone Payments | ZIOPHARM Oncology, Inc. |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |
Deferred revenue |  | 129,125 | 138,809
Upfront and Milestone Payments | Oragenics, Inc. |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |
Deferred revenue |  | 7,242 | 7,766
Upfront and Milestone Payments | Fibrocell Science, Inc. |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |
Deferred revenue |  | 17,816 | 19,026
Upfront and Milestone Payments | Genopaver, LLC |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |
Deferred revenue |  | 1,840 | 1,977
Upfront and Milestone Payments | Intrexon Energy Partners, LLC |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |
Deferred revenue |  | 16,875 | 18,125
Upfront and Milestone Payments | Persea Bio, LLC |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |
Deferred revenue |  | 3,750 | 4,000
Upfront and Milestone Payments | Ares Trading S.A. |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |
Deferred revenue |  | 43,984 | 47,178
Upfront and Milestone Payments | Intrexon Energy Partners II, LLC |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |
Deferred revenue |  | 14,833 | 15,833
Upfront and Milestone Payments | Intrexon T1D Partners, LLC |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |
Deferred revenue |  | 8,678 | 8,653
Upfront and Milestone Payments | Harvest start-up entities |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |
Deferred revenue | [1] | 19,400 | 20,208
Upfront and Milestone Payments | Other |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |
Deferred revenue |  | $ 14,719 | $ 16,292
[1] | As of June 30, 2017 and December 31, 2016, the balance of deferred revenue for collaborations with Harvest start-up entities includes Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DeferredRevenueArrangementLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_ProductOrServiceAxis=xon_UpfrontAndMilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_ZiopharmMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_OragenicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_FibrocellMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_GenopaverLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_IntrexonEnergyPartnersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_PerseaBioLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_AresTradingS.A.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_IntrexonEnergyPartnersIILLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_IntrexonT1DPartnersLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_HarvestStartUpEntitiesAggregatedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_OtherCollaborationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |